Literature DB >> 22628488

Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease.

Won-Jung Koh1, Byeong-Ho Jeong2, Kyeongman Jeon2, Nam Yong Lee3, Kyung Soo Lee4, Sook Young Woo5, Sung Jae Shin6, O Jung Kwon2.   

Abstract

BACKGROUND: Mycobacterium avium and Mycobacterium intracellulare are grouped together as the M avium complex; however, little is known about the clinical impact of this species differentiation. This study compared the clinical features and prognoses of patients with M avium and M intracellulare lung disease.
METHODS: From 2000 to 2009, 590 patients were given a new diagnosis of M avium complex lung disease; 323 (55%) had M avium lung disease, and 267 (45%) had M intracellulare lung disease.
RESULTS: Compared with the patients with M avium lung disease, the patients with M intracellulare lung disease were more likely to have the following characteristics: older age (64 vs 59 years, P = .002), a lower BMI (19.5 kg/m² vs 20.6 kg/m², P < .001), respiratory symptoms such as cough (84% vs 74%, P = .005), a history of previous treatment for TB (51% vs 31%, P < .001), the fibrocavitary form of the disease (26% vs 13%, P < .001), smear-positive sputum (56% vs 38%, P < .001), antibiotic therapy during the 24 months of follow-up (58% vs 42%, P < .001), and an unfavorable microbiologic response after combination antibiotic treatment (56% vs 74%, P = .001).
CONCLUSIONS: Patients with M intracellulare lung disease exhibited a more severe presentation and had a worse prognosis than patients with M avium lung disease in terms of disease progression and treatment response. Therefore, species differentiation between M avium and M intracellulare may have prognostic and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22628488     DOI: 10.1378/chest.12-0494

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  55 in total

1.  Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis.

Authors:  Stacey L Martiniano; Marci K Sontag; Charles L Daley; Jerry A Nick; Scott D Sagel
Journal:  Ann Am Thorac Soc       Date:  2014-01

2.  Mycobacterium Tuberculosis and Nontuberculous Mycobacteria Coinfection of the Lungs.

Authors:  Nafiye Yılmaz; Elif Yılmazel Uçar; Leyla Sağlam
Journal:  Turk Thorac J       Date:  2017-01-01

3.  Distribution of nontuberculous mycobacteria by multigene sequence-based typing and clinical significance of isolated strains.

Authors:  Mi-Ae Jang; Won-Jung Koh; Hee Jae Huh; Su-Young Kim; Kyeongman Jeon; Chang-Seok Ki; Nam Yong Lee
Journal:  J Clin Microbiol       Date:  2014-02-05       Impact factor: 5.948

4.  Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.

Authors:  Seong Mi Moon; Hye Yun Park; Byeong-Ho Jeong; Kyeongman Jeon; Soo-Youn Lee; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

5.  Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.

Authors:  Byung Woo Jhun; Seong Mi Moon; Su-Young Kim; Hye Yun Park; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Myung Jin Chung; Kyung Soo Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease.

Authors:  Byeong-Ho Jeong; Kyeongman Jeon; Hye Yun Park; Seong Mi Moon; Su-Young Kim; Soo-Youn Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.

Authors:  Seong Mi Moon; Hye Yun Park; Su-Young Kim; Byung Woo Jhun; Hyun Lee; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Seung-Heon Lee; Chang Ki Kim; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  Absence of Mycobacterium intracellulare and presence of Mycobacterium chimaera in household water and biofilm samples of patients in the United States with Mycobacterium avium complex respiratory disease.

Authors:  Richard J Wallace; Elena Iakhiaeva; Myra D Williams; Barbara A Brown-Elliott; Sruthi Vasireddy; Ravikiran Vasireddy; Leah Lande; Donald D Peterson; Janet Sawicki; Rebecca Kwait; Wellington S Tichenor; Christine Turenne; Joseph O Falkinham
Journal:  J Clin Microbiol       Date:  2013-03-27       Impact factor: 5.948

9.  Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.

Authors:  Won-Jung Koh; Goohyeon Hong; Su-Young Kim; Byeong-Ho Jeong; Hye Yun Park; Kyeongman Jeon; O Jung Kwon; Seung-Heon Lee; Chang Ki Kim; Sung Jae Shin
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

10.  Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease.

Authors:  Bo Young Lee; Sunyoung Kim; YoonKi Hong; Sang-Do Lee; Woo Sung Kim; Dong Soon Kim; Tae Sun Shim; Kyung-Wook Jo
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.